<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2312200358
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VALTREX
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALACICLOVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        86.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXO SAUDI ARABIA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AB11
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Valtrex belongs to a group of medicines called antivirals. It works by killing or stopping the growth of viruses called herpes simplex (HSV), varicella zoster (VZV) and cytomegalovirus (CMV).</p><p>Valtrex can be used to:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->treat shingles (in adults)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->treat HSV infections of the skin and genital herpes (in adults and adolescents over 12 years old). It is also used to help prevent these infections from returning.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->treat cold sores (in adults and adolescents over 12 years old)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->prevent infection with CMV after organ transplants (in adults and adolescents over 12 years old)</p><p>treat and prevent HSV infections of the eye that continue to come back (in adults and adolescents over 12 years old)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Don&rsquo;t take Valtrex</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are allergic to valaciclovir or aciclovir or any of the other ingredients of this medicine (listed in Section 6).</p><p><!--[if !supportLists]-->&egrave;&nbsp;&nbsp; <!--[endif]-->Don&rsquo;t take Valtrex if the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking Valtrex.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>Check with your doctor or pharmacist before taking Valtrex if:</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>you have kidney problems</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>you have liver problems</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>you are over 65 years of age</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>your immune system is weak</strong></p><p><strong>&nbsp;</strong></p><p><strong>If you are not sure if the above apply to you, talk to your doctor or pharmacist before taking Valtrex.</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Prevent passing genital herpes on to others</u></strong></p><p><strong>If you are taking Valtrex to treat or prevent genital herpes, or you have had genital herpes in the past, you should still practice safe sex, including the use of condoms. This is important to prevent you passing the infection on to others. You should not have sex if you have genital sores or blisters.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Valtrex</strong></p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes medicines obtained without a prescription, including herbal medicines<em>. </em></p><p><em><u>&nbsp;</u></em></p><p>Tell your doctor or pharmacist if you are taking any other medicines that affect the kidneys. These include: aminoglycosides, organoplatinum compounds, iodinated contrast media, methotrexate, pentamidine, foscarnet, ciclosporin, tacrolimus, cimetidine and probenecid.</p><p>&nbsp;</p><p>Always tell your doctor or pharmacist about other medicines<strong><em> </em></strong>if you are taking Valtrex for treatment of shingles or after having an organ transplant.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>Valtrex is not usually recommended for use during pregnancy. If you are pregnant, or think you could be, or if you are planning to become pregnant, don&rsquo;t take Valtrex without checking with your doctor. Your doctor will weigh up the benefit to you against the risk to your baby of taking Valtrex while you&#39;re pregnant or breastfeeding.</p><p>&nbsp;</p><p><strong>Driving or using machines</strong></p><p>Valtrex can cause side effects that affect your ability to drive.</p><p>&agrave; Don&rsquo;t drive or use machines unless you are sure you&rsquo;re not affected.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>The dose that you should take will depend on why your doctor has prescribed Valtrex for you. Your doctor will discuss this with you.</p><p>&nbsp;</p><p><u>Treatment of shingles</u></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The usual dose is 1000 mg (one 1000 mg tablet or two 500 mg tablets) three times a day.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->You should take Valtrex for seven days.</p><p>&nbsp;</p><p><u>Treatment of cold sores</u></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The usual dose is 2000 mg (two 1000 mg tablets or four 500 mg tablets) twice a day.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The second dose should be taken 12 hours (no sooner than 6 hours) after the first dose</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->You should take Valtrex for one day (two doses) only.</p><p>&nbsp;</p><p><u>Treatment of HSV infections of the skin and genital herpes </u></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The usual dose is 500 mg (one 500 mg tablet or two 250 mg tablets) twice a day.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->For the first infection you should take Valtrex for five days or for up to ten days if your doctor tells you to. For recurrent infection the duration of treatment is normally 3-5 days.</p><p>&nbsp;</p><p><u>Helping to prevent HSV infections from returning</u><u> after you have had them</u></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The usual dose is one 500&nbsp;mg tablet once a day.</p><p><!--[if !supportLists]--><s>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s><!--[endif]-->Some people with frequent recurrences may benefit from taking one 250&nbsp;mg tablet twice a day<strong>.</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->You should take Valtrex until your doctor tells you to stop.<strong> </strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><u>To stop you being infected with CMV (<em>Cytomegalovirus</em></u>)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The usual dose is 2000 mg (two 1000 mg tablets or<strong> </strong>four 500&nbsp;mg tablets) four times a day.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->You should take each dose about 6 hours apart.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->You will usually start taking Valtrex as soon as possible after your surgery.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->You should take Valtrex for around 90 days after your surgery, until your doctor tells you to stop.<strong> </strong></p><p><strong>&nbsp;</strong></p><p><u>Your doctor may adjust the dose of Valtrex if:</u></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->you are over 65&nbsp;years of age</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->you have a weak immune system</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->you have kidney problems.</p><p><!--[if !supportLists]-->&egrave;&nbsp;&nbsp; <!--[endif]-->Talk to your doctor before taking Valtrex if any of the above apply.</p><p>&nbsp;</p><p><strong>Taking this medicine</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Take this medicine by mouth.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Swallow the tablets whole with a drink of water.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Take Valtrex at the same time each day.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Take Valtrex according to instructions from your doctor or pharmacist.</p><p><strong>&nbsp;</strong></p><p><strong>People over 65&nbsp;years of age or with kidney problems</strong></p><p><strong>&nbsp;</strong></p><p><strong>It is very important while you are taking Valtrex that you drink water regularly</strong> during the day. This will help to reduce side effects that can affect the kidney or nervous system. Your doctor will closely monitor you for signs of these. Nervous system side effects might include feeling confused or agitated, or feeling unusually sleepy or drowsy.</p><p>&nbsp;</p><p><strong>If you take more Valtrex than you should</strong></p><p>Valtrex is not usually harmful, unless you take too much over several days. If you take too many tablets you may feel sick, vomit, get kidney problems, may be confused, agitated, feel less aware, see things that aren&rsquo;t there or become unconscious.&nbsp; Talk to your doctor or pharmacist if you take too much Valtrex. Take the medicine pack with you.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take Valtrex</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you forget to take Valtrex, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Don&rsquo;t take a double dose to make up for a forgotten dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p>&nbsp;</p><p><strong>Conditions you need to look out for</strong></p><p><strong>&nbsp;</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe allergic reactions (anaphylaxis). These are rare in people taking Valtrex. Rapid development of symptoms including:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->flushing, itchy skin rash</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->swelling of the lips, face, neck and throat, causing difficulty in breathing (angiodema)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->fall in blood pressure leading to collapse.</p><p><!--[if !supportLists]-->&egrave;&nbsp;&nbsp; <!--[endif]-->If you have an allergic reaction, stop taking Valtrex and see a doctor straight away.</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10 people)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->headache</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->feeling sick</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100 people)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->shortness of breath (dyspnoea)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->skin reaction after exposure to sunlight (photosensitivity)</p><p>&nbsp;</p><p><strong>Rare</strong> (may affect up to 1 in 1,000 people)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->dizziness</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->feeling confused</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->seeing or hearing things that aren&rsquo;t there (hallucinations)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->feeling very drowsy</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->stomach discomfort</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->vomiting</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->diarrhoea</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->itching (pruritis)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->low back pain (kidney pain)</p><p>&nbsp;</p><p>These nervous system side effects usually occur in people with kidney problems, the elderly or in organ transplant patients taking high doses of 8&nbsp;grams or more of Valtrex a day. They usually get better when Valtrex is stopped or the dose reduced.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Very rare </strong>(may affect up to 1 in 10,000 people)</p><p>&nbsp;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->reduction in the number of white blood cells (leucopenia)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->reduction in the number of blood platelets which are cells that help blood to clot (thrombocytopenia)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe allergic reactions (anaphylaxis)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->feeling agitated</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Tremors</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->unsteadiness when walking and lack of coordination (ataxia)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->slow, slurred speech (dysarthria)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->confused or disturbed thoughts (delirium)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->fits (convulsions)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->altered brain function (encephalopathy)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->unconsciousness (coma)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Reversible increase in liver function tests.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->hive-like rash (urticaria)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->swelling of the lips, face, neck and throat, causing difficulty in breathing (angiodema)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Acute renal failure</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->low back pain (kidney pain)</p><p>&nbsp;</p><p>&nbsp;</p><p>These nervous system side effects usually occur in people with kidney problems, the elderly or in organ transplant patients taking high doses of 8&nbsp;grams or more of Valtrex a day. They usually get better when Valtrex is stopped or the dose reduced.</p><p>&nbsp;</p><p><u>Other not known</u><u> side effects:</u></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Inability of the kidney to carry out normal function.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->damage of the red blood cells</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->reduction in the number of blood platelets which are cells that help blood to clot (thrombocytopenia)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Keep this medicine out of the sight and reach of children.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not use Valtrex after the expiry date which is stated on the pack after &lsquo;Exp&rsquo;.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Store below 30&deg;C.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If your doctor tells you to stop taking Valtrex, it is important to return any remnants which are left over to your pharmacist.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Valtrex contains</strong></p><p><strong>&nbsp;</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The active substance is valaciclovir. Each tablet contains 500 mg of valaciclovir (as valaciclovir hydrochloride).</p><p>The other ingredients are:</p><p><u>&nbsp;</u></p><p><u>Tablet core</u></p><p>Microcrystalline cellulose</p><p>Crospovidone</p><p>Povidone</p><p>Magnesium stearate</p><p>Colloidal silicon dioxide</p><p>Purified water</p><p>&nbsp;</p><p><u>Film coat</u></p><p>Hydroxypropylmethycellulose</p><p>Titanium dioxide</p><p>Polyethylene glycol</p><p>Polysorbate 80 (500 and 1000 mg tablets only)</p><p>Purified water</p><p>Carnauba wax</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Valtrex tablets look like and contents of the pack
	
Tablets are packed into blister packs prepared from unplasticised polyvinylchloride and aluminium foil.
	
Valtrex Tablets 500 mg is supplied in cartons containing film-coated tablets. They are white to off white core, biconvex, elongated, un-scored, and marked with “GX CF1” by engraving on one side.

Not all packs are available in every country.
Valtrex is a trade marks owned by or licensed to the GSK group of companies.
© 2020 GSK group of companies, all rights reserved.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by:</strong></p><p>Glaxo Wellcome S.A.*, Aranda, Spain</p><p>Avenida de Extremadura, 3. 09400 Aranda de Duero, Burgos (Spain)</p><p><strong>Packaged by</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, Kingdom of Saudi Arabia</p><p><strong>Marketing Authorisation Holder </strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>*member of the GlaxoSmithKline group of companies</p><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GlaxoSmithKline - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: gcc.medinfo@gsk.com</li><li>Website: https://gskpro.com/en-sa/<u> </u></li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><table style="width:500px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Fax: +966-11-205-7662</li><li>Call NPC at +966-11-2038222, Ext: 2317-2356-2340</li><li>Reporting Hotline: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc<u> </u></li></ul><p><strong>-GlaxoSmithKline - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: <u>s</u>audi.safety@gsk.com<u>&nbsp; </u></li><li>Website: https://gskpro.com/en-sa/<u> </u></li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul></td></tr></tbody></table><table style="width:500px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>THIS IS A MEDICAMENT</strong></p><p>- Medicament is a product which affects your health, and its consumption contrary to</p><p>&nbsp;&nbsp; instructions is dangerous for you.</p><p>- Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the&nbsp;&nbsp;</p><p>&nbsp;&nbsp; pharmacist who sold the medicament.</p><p>- The doctor and the pharmacist are experts in medicine, its benefits and risks.</p><p>- Do not by yourself interrupt the period of treatment prescribed for you.</p><p>- Do not repeat the same prescription without consulting your doctor.</p><p>- Keep all medicine out of reach of children</p><p>Council of Arab Health Ministers</p><p>Union of Arab Pharmacists</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Extracted from: GDS22/IPI04
Date of issue: 18 Jun 2012

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;</p><p>ينتمي ڤالتيركس إلى مجموعة من الأدوية تسمى مضادات الفيروسات. ويظهر تأثيره العلاجي من خلال قتل فيروسات تسمى فيروس الهربس البسيط (HSV)، والفيروس النُطاقي الحُماقي (VZV)، والفيروس المُضخّم للخلايا (CMV)، أو إيقاف نمو تلك الفيروسات.</p><p>يمكن استخدام ڤالتيركس للأغراض التالية:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->علاج الهربس النُطاقي (بين البالغين)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->علاج العدوى بفيروس الهربس البسيط (HSV) التي تصيب البشرة، وهربس الأعضاء التناسلية (بين البالغين والمراهقين ممن تزيد أعمارهم عن 12 عامًا). كما يُستخدم أيضًا للمساعدة في منع تكرار حدوث تلك العدوى.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->علاج قرحات الزكام (بين البالغين والمراهقين ممن تزيد أعمارهم عن 12 عامًا)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->منع العدوى بالفيروس المُضخّم للخلايا (CMV) بعد عمليات زراعة الأعضاء (بين البالغين والمراهقين ممن تزيد أعمارهم عن 12 عامًا)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->علاج عدوى فيروس الهربس البسيط (HSV) التي تصيب العين والتي تتكرر بصورة مستمرة، ومنع حدوث العدوى<br />(بين البالغين والمراهقين ممن تزيد أعمارهم عن 12 عامًا)<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا ينبغي تناول ڤالتيركس في الحالات التالية</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->في حالة وجود حساسية لمادة الفالاسيكلوفير أو الأسيكلوفير أو لأيّ مكوّن من المكوّنات الأخرى الخاصة بهذا الدواء (المذكورة في القسم 6).</p><p><!--[if !supportLists]-->&ccedil;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لا ينبغي تناول ڤالتيركس إذا كان ما ذُكر أعلاه ينطبق عليك. وفي حالة عدم التأكد من ذلك، ينبغي استشارة الطبيب أو الصيدلاني قبل تناول ڤالتيركس.</p><p>&nbsp;</p><p><strong>تحذيرات واحتياطات</strong></p><p><strong>ينبغي استشارة الطبيب أو الصيدلاني قبل تناول ڤالتيركس في الحالات التالية:</strong></p><p><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>عند وجود مشكلات في الكلى</strong></p><p><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>عند وجود مشكلات في الكبد</strong></p><p><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>عندما يزيد السن عن 65 عامًا</strong></p><p><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>عند ضعف الجهاز المناعي</strong></p><p><strong>&nbsp;</strong></p><p><strong>وفي حالة عدم التأكد مما إذا كان ما ذُكر أعلاه ينطبق عليك، ينبغي استشارة الطبيب أو الصيدلاني قبل تناول ڤالتيركس.</strong></p><p>&nbsp;</p><p><strong><u>منع انتقال هربس الأعضاء التناسلية للآخرين</u></strong></p><p><strong>في حالة تناول ڤالتيركس لعلاج هربس الأعضاء التناسلية أو منع الإصابة به، أو كنت تعاني في السابق من هربس الأعضاء التناسلية، لا يزال ينبغي عليك ممارسة الجنس الآمن، ويتضمن ذلك استخدام الواقي الذكري. وهذا هام لمنع انتقال العدوى منك إلى الآخرين. ينبغي عدم ممارسة الجنس في حالة الإصابة بقرحات أو نفطات بمنطقة الأعضاء التناسلية.</strong></p><p>&nbsp;</p><p><strong>الأدوية الأخرى وڤالتيركس</strong></p><p>ينبغي إخبار الطبيب أو الصيدلاني إذا كنت تتناول أية أدوية أخرى أو تناولت أية أدوية أخرى مؤخرًا. ويشمل ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية، بما في ذلك الأدوية العشبية.</p><p><em><u>&nbsp;</u></em></p><p>ينبغي إخبار الطبيب أو الصيدلاني إذا كنت تتناول أية أدوية أخرى تؤثر على الكلى. وتشمل تلك الأدوية: الأمينوجلايكوسيدات، ومركبات البلاتين العضوية، والوسائط التباينية المعالجة باليود، والميثوتريكسات، والبنتاميدين، وفوسكارنت، وسيكلوسبورين، وتاكروليموس، وبروبينيسيد.</p><p>&nbsp;</p><p>ينبغي دائمًا إخبار الطبيب أو الصيدلاني عن الأدوية الأخرى في حالة تناول ڤالتيركس لعلاج الهربس النُطاقي أو بعد إجراء عملية زراعة لأحد الأعضاء.</p><p><strong>&nbsp;</strong></p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p>لا يوصى باستخدام ڤالتيركس في المعتاد خلال فترة الحمل. فإذا كنتِ حاملاً، أو تظنين أنك حامل، أو إذا كنتِ تنوين الحمل، لا ينبغي تناول ڤالتيركس بدون استشارة الطبيب. سوف يقدّر الطبيب الفائدة التي تعود عليكِ في مقابل الخطر الذي قد يُهدد الجنين عند تناول ڤالتيركس أثناء فترة الحمل أو الرضاعة.</p><p>&nbsp;</p><p><strong>القيادة أو استخدام الآلات</strong></p><p>قد يسبب ڤالتيركس آثارًا جانبيةً تؤثر على القدرة على القيادة.</p><p>&szlig; وينبغي عدم القيادة أو استخدام الآلات إلا في حالة التأكد من عدم التأثُر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب الالتزام بتعليمات الطبيب دائمًا بشأن طريقة تناول هذا الدواء. كما يجب عليك استشارة الطبيب أو الصيدلاني إذا لم تكن واثقًا من هذا الشأن.</p><p>&nbsp;</p><p>تعتمد الجرعة التي ينبغي تناولها على سبب وصف الطبيب لڤالتيركس لك. وسوف يناقش الطبيب ذلك معك.</p><p>&nbsp;</p><p><u>علاج الهربس النُطاقي</u></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الجرعة العادية هي 1000 ملجم (قرص واحد 1000 ملجم أو قرصان 500 ملجم) ثلاث مرات يوميًا.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->وينبغي تناول ڤالتيركس لمدة سبعة أيام.</p><p>&nbsp;</p><p><u>علاج قرحات الزكام</u></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الجرعة العادية هي 2000 ملجم (قرصان 1000 ملجم أو أربعة أقراص 500 ملجم) مرتين في اليوم.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->وينبغي تناول الجرعة الثانية بعد مرور 12 ساعةً (وليس قبل 6 ساعات) بعد تناول الجرعة الأولى</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ينبغي تناول ڤالتيركس ليوم واحد (جرعتان) فقط.</p><p>&nbsp;</p><p><u>حالات عدوى فيروس الهربس البسيط </u><u>(HSV)</u><u> التي تصيب البشرة، وهربس الأعضاء التناسلية </u></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الجرعة العادية هي 500 ملجم (قرص 500 ملجم أو قرصان 250 ملجم) مرتين في اليوم.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->وعند حدوث العدوى للمرة الأولى ينبغي تناول ڤالتيركس لمدة خمسة أيام أو حتى عشرة أيام إذا نصح الطبيب بذلك. وبالنسبة للعدوى المتكررة، تكون مدة العلاج المعتادة من 3 إلى 5 أيام.</p><p>&nbsp;</p><p><u>المساعدة في منع تكرار العدوى بفيروس الهربس البسيط</u></p><p><u>(</u><u>HSV)<u> </u></u></p><p><u>بعد الإصابة به</u></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الجرعة العادية هي قرص واحد 500 ملجم مرة في اليوم.</p><p><!--[if !supportLists]--><s>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s><!--[endif]-->قد يستفيد بعض الأشخاص ممن تتكرر العدوى لديهم من تناول قرص واحد 250 ملجم مرتين في اليوم.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->وينبغي تناول ڤالتيركس حتى ينصح الطبيب بالتوقف عن تناوله.</p><p><strong>&nbsp;</strong></p><p><u>لإيقاف العدوى بفيروس </u></p><p><u>CMV</u><u> </u></p><p><u>(</u>الفيروس المُضخّم للخلايا)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الجرعة العادية هي 2000 ملجم (قرصان 1000 ملجم أو أربعة أقراص 500 ملجم) أربع مرات في اليوم.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->وينبغي أخذ كل جرعة بعد حوالي 6 ساعات.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->وسيتم بدء تناول ڤالتيركس في العادة في أسرع وقت ممكن بعد الجراحة.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ينبغي تناول ڤالتيركس لمدة 90 يومًا تقريبًا بعد الجراحة، حتى ينصح الطبيب بالتوقف عن تناوله.</p><p><strong>&nbsp;</strong></p><p><u>قد يقوم الطبيب بتعديل جرعة ڤالتيركس في الحالات التالية:</u></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->عندما يزيد السن عن 65 عامًا</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->عند المعاناة من ضعف في الجهاز المناعي</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->عند وجود مشكلات في الكلى.</p><p><!--[if !supportLists]-->&ccedil;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ينبغي استشارة الطبيب قبل تناول ڤالتيركس أو في حالة وجود أيّ مما سبق.</p><p>&nbsp;</p><p><strong>طريقة تناول هذا الدواء</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تناول هذا الدواء عن طريق الفم.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ينبغي بلع الأقراص بأكملها مع شرب الماء.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تناول ڤالتيركس في الوقت نفسه كل يوم.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تناول ڤالتيركس وفقًا لتعليمات الطبيب أو الصيدلاني.</p><p><strong>&nbsp;</strong></p><p><strong>الأشخاص الذين تزيد أعمارهم عن 65 عامًا أو يعانون من مشكلات في الكلى</strong></p><p><strong>&nbsp;</strong></p><p><strong>من المهم للغاية أثناء تناول ڤالتيركس شرب الماء بشكل منتظم</strong> خلال اليوم. حيث سيساعد ذلك في تقليل الآثار الجانبية التي قد تؤثر على الكلى أو الجهاز العصبي. سوف يتابعك الطبيب عن كثب لملاحظة أية علامات لهذه الأعراض. قد تتضمن الآثار الجانبية على الجهاز العصبي الشعور بالارتباك أو الهياج، أو الشعور بالخمول أو النعاس غير المعتاد.</p><p>&nbsp;</p><p><strong>في حالة تناول جرعة ڤالتيركس زائدة عن ما ينبغي تناوله</strong></p><p>ڤالتيركس غير ضارٍ في المعتاد، إلا إذا تم تناول قدر كبير للغاية خلال عدة أيام. وفي حالة تناول كمية كبيرة جدًا من الأقراص، فقد تشعر بالإعياء أو القيء أو حدوث مشكلات في الكلى أو الارتباك أو الهياج أو الشعور بنقص في الإدراك أو مشاهدة أشياء غير موجودة أو فقدان الوعي. استشر الطبيب أو الصيدلاني في حالة تناول قدر كبير للغاية من ڤالتيركس. وخذ عبوة الدواء معك.</p><p><strong>&nbsp;</strong></p><p><strong>في حالة نسيان تناول ڤالتيركس</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->في حالة نسيان تناول ڤالتيركس، ينبغي تناوله في أسرع وقت بمجرد تذكر ذلك. لكن إذا كان قد حان وقت الجرعة التالية تقريبًا، فينبغي عدم تناول الجرعة الفائتة.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لا تتناول جرعة مضاعفة لتعويض الجرعة التي فاتتك.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال في جميع الأدوية، يمكن أن يتسبب هذا الدواء في حدوث آثار جانبية، لكن لا يصاب بها جميع الأشخاص. قد تحدث الآثار الجانبية التالية عند تناول الدواء:</p><p>&nbsp;</p><p><strong>حالات ينبغي الانتباه لها</strong></p><p><strong>&nbsp;</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تفاعلات الحساسية الحادة (التأق). هذه التفاعلات نادرة في حالة الأشخاص الذين يتناولون ڤالتيركس. يشمل التطور السريع للأعراض ما يلي:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->احمرار الجلد، الطفح الجلدي المثير للحكة</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تورم الشفتين والوجه والعنق والحلق، مما يؤدي إلى صعوبة في التنفس (الوذمة الوعائية)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->انخفاض في ضغط الدم يؤدي إلى السقوط.</p><p><!--[if !supportLists]-->&ccedil;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->في حالة الإصابة بتفاعل الحساسية، ينبغي التوقف عن تناول ڤالتيركس واستشارة طبيب على الفور.</p><p>&nbsp;</p><p><strong>الآثار الجانبية الشائعة </strong>(قد تصيب شخصًا بين كل 10 أشخاص)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الصداع</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الشعور بالإعياء</p><p>&nbsp;</p><p><strong>الآثار الجانبية غير الشائعة</strong> (قد تصيب شخصًا بين كل 100 شخص)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضيق في التنفس (ضيق النفس)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تفاعل البشرة بعد التعرض لضوء الشمس (الحساسية للضوء)</p><p>&nbsp;</p><p><strong>الآثار الجانبية النادرة</strong> (قد تصيب شخصًا بين كل 1000 شخص)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->دوار</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الشعور بالارتباك</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->رؤية أو سماع أشياء غير موجودة (الهلاوس)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الشعور بالنعاس الشديد</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مغص في المعدة</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->القيء</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الإسهال</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الحكة (الحكة الجلدية)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم في أسفل الظهر (ألم في الكلى)</p><p>&nbsp;</p><p>عادة ما تظهر هذه الآثار الجانبية التي تصيب الجهاز العصبي في الأشخاص الذين يعانون من مشكلات في الكلى أو كبار السن أو مرضى زراعة الأعضاء الذين يتناولون جرعات كبيرة بمقدار 8 جرام أو أكثر من ڤالتيركس في اليوم. وعادةً ما يشعرون بتحسن عند التوقف عن تناول ڤالتيركس أو تقليل الجرعة.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>الآثار النادرة جدًا</strong> (قد يتأثر شخص بين كل 10000 شخص)</p><p>&nbsp;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->انخفاض في عدد خلايا الدم البيضاء (قلة الكريات البيض)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->انخفاض في عدد الصفائح الدموية وهي خلايا تساعد الدم في التجلط (نقص الصفائح الدموية)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تفاعلات الحساسية الحادة (التأق)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الشعور بالهياج</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الرعاش</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->عدم الثبات أثناء المشي وفقد الاتزان (الترنح)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الكلام ببطء وتداخل الكلام (عسر التلفظ)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الارتباك أو تشوش الأفكار (الهذيان)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->نوبات (تشنجات)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تغيّر في وظيفة المخ (الاعتلال الدماغي)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فقدان الوعي (الغيبوبة)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->زيادة عكسية في اختبارات وظائف الكبد.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->طفح يشبه الانتبار (الشرى)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تورم الشفتين والوجه والعنق والحلق، مما يؤدي إلى صعوبة في التنفس (الوذمة الوعائية)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الفشل الكلوي الحاد</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم في أسفل الظهر (ألم في الكلى)</p><p>&nbsp;</p><p>&nbsp;</p><p>تحدث الآثار الجانبية الخاصة بالنظام العصبي في المعتاد في حالة الأشخاص الذين يعانون من مشكلات في الكلى أو كبار السن أو مرضى زراعة الأعضاء الذين يتناولون جرعات كبيرة بمقدار 8 جرام أو أكثر من ڤالتيركس في اليوم. وعادةً ما يشعرون بتحسن عند التوقف عن تناول ڤالتيركس أو تقليل الجرعة.</p><p>&nbsp;</p><p><u>الآثار الجانبية</u><u> الأخرى غير المعروفة:</u></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->عدم قدرة الكلى على القيام بوظيفتها الطبيعية</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تلف خلايا الدم الحمراء</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->انخفاض في عدد الصفائح الدموية وهي خلايا تساعد الدم في التجلط (نقص الصفائح الدموية)</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يجب حفظ الدواء بعيدًا عن متناول ومرأى الأطفال.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يجب عدم استخدام ڤالتيركس بعد تاريخ انتهاء فترة الصلاحية المذكور على العبوة.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ينبغي تخزين الدواء في درجة حرارة أقل من 30 درجة مئوية.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا نصح الطبيب بضرورة التوقف عن تناول ڤالتيركس، فمن الضروري إعادة ما تبقى منه إلى الصيدلاني.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لا يجوز التخلّص من الأدوية بإلقائها في مياه الصرف أو المخلفات المنزلية. اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. فهذه الإجراءات من شأنها المحافظة على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>مكوّنات ڤالتيركس</strong></p><p><strong>&nbsp;</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المادة الفعَّالة هي الفالاسيكلوفير. يحتوي كل قرص على 500 ملجم من مادة الفالاسيكلوفير (في صورة هيدروكلوريد فالاسيكلوفير).</p><p>المكوّنات الأخرى هي:</p><p><u>&nbsp;</u></p><p><u>لب القرص</u></p><p>سيليلوز دقيق التبلور</p><p>كروسبوفيدون</p><p>بوفيدون</p><p>ستيرات الماغنيسيوم</p><p>ثاني أكسيد السيليكون الغرواني</p><p>ماء مقطَّر</p><p>&nbsp;</p><p><u>غلاف القرص</u></p><p>هيدروكسي بروبيل ميثيل سليلوز</p><p>ثاني أكسيد التيتانيوم</p><p>البولي إيثيلين جليكول</p><p>بوليسوربات 80 (أقراص 500 و1000 ملجم فقط)</p><p>ماء مقطَّر</p><p>شمع كرنوبا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            	شكل أقراص ڤالتيركس ومحتويات العبوة
	
تتم تعبئة الأقراص في شرائط فقاعية مصممة من البولي فينيل كلوريد غير الملدّن ورقاقات الألومنيوم.
	
يتم توفير أقراص ڤالتيركس 500 ملجم في عبوات كرتونية تحتوي على أقراص مغلفة. قرص مغلّف أبيض إلى شبه أبيض، والأقراص طويلة الشكل ومحدبة الوجهين ومحفور على أحد جانبيها "GX CF1".

لا تتوافر جميع العبوات في كل بلد.
ڤالتيركس علامة تجارية مملوكة او مرخصة لمجموعة شركات جلاكسو سميث كلاين.
© 2020 جلاكسو سميث كلاين، جميع الحقوق محفوظة.

        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>تصنيع:</strong></p><p>جلاكسو ويلكام أس.أيه.*، أرندا&nbsp; ـ أسبانيا</p><p>شارع إكستريماديورا، 09400 ,3 أراندا دو ديورو، برجوس، أسبانيا</p><p><strong>تعبئة:</strong></p><p>جلاكسو العربية السعودية المحدودة*، جدة، المملكة العربية السعودية.</p><p><strong>صاحبة رخصة التسويق</strong></p><p>جلاكسو العربية السعودية المحدودة *، جدة، المملكة العربية السعودية.</p><p>*عضو مجموعة شركات جلاكسو سميث كلاين.</p><p><strong>&nbsp;</strong></p><p><strong>للإستفسار عن أي معلومات عن هذا المستحضر الدوائي، يرجى الإتصال بالأرقام التالية:</strong></p><p>جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->هاتف: 6536666-12-966+</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->جوال: -56-904-9882966+</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->البريد الإلكتروني: gcc.medinfo@gsk.com</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الموقع الإلكتروني: https://gskpro.com/en-sa/</p><p><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]-->ص.ب. 55850، جدة 21544، المملكة العربية السعودية<strong>.</strong></p><table style="width:500px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>للإبلاغ عن أي آثار جانبية:</strong></p><p><strong><em>المملكة العربية السعودية</em></strong></p><p><strong>- المركز القومي للتيقظ والسلامة الدوائية (</strong><strong>NPC</strong><strong>)</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فاكس: 7662-205-11-966 +</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الاتصال بالمركز الوطني للتيقظ والسلامة الدوائية. هاتف: 2038222-11-966+ تحويلة: 2317-2356-2353-2340</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الموقع الإلكتروني: www.sfda.gov.sa/npc</p><p><strong>- جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->هاتف: 6536666-12-966+</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->جوال: -56-904-9882966+</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->البريد الإلكتروني: saudi.safety@gsk.com</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الموقع الإلكتروني: https://gskpro.com/en-sa/</p>&nbsp;&nbsp;&nbsp;&nbsp; ص.ب. 55850، جدة 21544، المملكة العربية السعودية</td></tr></tbody></table><p>&nbsp;</p><table style="width:500px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>إن هذا دواء</strong></p><p>- الدواء مستحضر يؤثر على صحتك، واستهلاكه خلافا للتعليمات يعرضك للخطر.</p><p>- اتبع بدقة وصفة الطبيب، وطريقة الاستعمال المنصوص عليها، وتعليمات الصيدلاني الذي صرفها لك.</p><p>- فالطبيب و الصيدلاني هما الخبيران بالدواء، وبنفعه و ضرره.</p><p>- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p>- لا تكرر صرف الدواء بدون استشارة الطبيب.</p><p>- احتفظ بجميع الأدوية بعيداً عن متناول الأطفال.&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مجلس وزراء الصحة العرب &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; اتحاد الصيادلة العرب</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مستخرج من : GDS22/IPI04
تاريخ الإصدار:  18 يونيو 2012

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VALTREX tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets containing 250 mg, 500 mg or 1000 mg of valaciclovir.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White film coated tablet, white to off white core, biconvex, elongated, unscored, branded ‘GX CF1’ by engraving containing 500 mg of valaciclovir.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>VALTREX</em> is indicated for the treatment of herpes zoster (shingles). <em>VALTREX</em> accelerates the resolution of pain: it reduces the duration of and the proportion of patients with zoster-associated pain, which includes acute and post-herpetic neuralgia.</p><p><em>VALTREX</em> is indicated for the treatment of herpes simplex infections of the skin and mucous membranes, including initial and recurrent genital herpes.</p><p><em>VALTREX</em> is indicated for the treatment of herpes labialis (cold sores).</p><p><em>VALTREX</em> is indicated for the prevention (suppression) of recurrent herpes simplex infections of the skin and mucous membranes, including genital herpes.</p><p>VALTREX can reduce transmission of genital herpes when taken as suppressive therapy and combined with safer sex practices.</p><p><em>VALTREX</em> is indicated for the prophylaxis of cytomegalovirus (CMV) infection and disease, following organ transplantation. CMV prophylaxis with <em>VALTREX</em> reduces acute graft rejection (renal transplant patients), opportunistic infections and other herpes virus infections (herpes simplex virus (HSV), varicella zoster virus (VZV)).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li><strong>Adults</strong></li></ul><p>Treatment of herpes zoster (shingles) including ophthalmic zoster</p><p>The dosage is 1000&nbsp;mg of <em>VALTREX</em> to be taken three times daily for seven days.</p><p>Treatment of herpes simplex infections</p><p>Immunocompetent adults and adolescents (12 years and older)</p><p>The dosage is 500&nbsp;mg of <em>VALTREX</em> to be taken twice daily.</p><p>For recurrent episodes, treatment should be for three or five days. For initial episodes, which can be more severe, treatment may have to be extended from five days to ten days. Dosing should begin as early as possible. For recurrent episodes of herpes simplex, this should ideally be during the prodromal period or immediately the first signs or symptoms appear.<em> VALTREX</em> can prevent lesion development when taken at the first signs and symptoms of an HSV recurrence.</p><p>Alternatively, for herpes labialis (cold sores), VALTREX 2&nbsp;g twice-daily for one day is effective treatment. The second dose should be taken about 12 hours (no sooner than 6 hours) after the first dose. When using this dosing regimen, treatment should not exceed one day, since this has been shown not to provide additional clinical benefit. Therapy should be initiated at the earliest symptom of a cold sore (e.g. tingling, itching or burning).</p><p>Prevention (suppression) of recurrences of herpes simplex infections</p><p>Immunocompetent adults and adolescents (12 years and older)</p><p>In immunocompetent patients, 500&nbsp;mg of <em>VALTREX</em> to be taken once daily.</p><p>Some patients with very frequent recurrences (e.g. 10 or more per year) may gain additional benefit from the daily dose of 500&nbsp;mg being taken as a divided dose (250&nbsp;mg twice daily).</p><p>Immunocompromised adults</p><p>For immunocompromised patients the dose is 500&nbsp;mg twice daily.</p><p>Reduction of transmission of genital herpes</p><p>In immunocompetent heterosexual adults with 9 or fewer recurrences per year, 500&nbsp;mg of <em>VALTREX</em> to be taken once daily by the infected partner.</p><p>There are no data on the reduction of transmission in other patient populations.</p><p>Prophylaxis of cytomegalovirus (CMV) infection and disease</p><p>The dosage of <em>VALTREX</em> in adults and adolescents (from 12 years of age) is 2&nbsp;g four times a day, to be initiated as early as possible post-transplant. This dose should be reduced according to creatinine clearance (<em>see Renal Impairment below</em>).</p><p>The duration of treatment will usually be 90 days, but may need to be extended in high risk patients.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Children</strong></p><p>There are no data available on the use of <em>VALTREX</em> in children.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Elderly</strong></p><p>The possibility of renal impairment in the elderly must be considered and the dosage should be adjusted accordingly (<em>see Renal impairment below</em>).</p><p>Adequate hydration should be maintained.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Renal impairment</strong></p><p>Caution is advised when administering valaciclovir to patients with impaired renal function. Adequate hydration should be maintained.</p><p>The dosage of <em>VALTREX</em> should be reduced in patients with significantly impaired renal function as shown in the table below:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:2.7in"><p><strong>Therapeutic indication</strong></p></td><td style="vertical-align:top; width:117.0pt"><p><strong>Creatinine clearance mL/min</strong></p></td><td style="vertical-align:top; width:131.25pt"><p><strong><em>Valaciclovir dosage</em></strong></p></td></tr><tr><td style="vertical-align:top; width:2.7in"><p>Herpes zoster (treatment) in immunocompetent and immunocompromised adults</p></td><td style="vertical-align:top; width:117.0pt"><p>at least 50</p><p>30 to 49</p><p>10 to 29</p><p>less than 10</p></td><td style="vertical-align:top; width:131.25pt"><p><em>1 g three times a day</em></p><p><em>1&nbsp;g twice a day</em></p><p><em>1&nbsp;g once a day</em></p><p><em>500 mg once a day</em></p></td></tr><tr><td style="vertical-align:top; width:2.7in"><p>Herpes simplex (treatment)</p></td><td style="vertical-align:top; width:117.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:131.25pt"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top; width:2.7in"><p>- immunocompetent adults and adolescents</p></td><td style="vertical-align:top; width:117.0pt"><p>at least 30</p><p>less than 30</p></td><td style="vertical-align:top; width:131.25pt"><p><em>500 mg twice a day</em></p><p><em>500 mg once a day</em></p></td></tr><tr><td style="vertical-align:top; width:2.7in"><p>Herpes labialis (treatment) in immunocompetent adults and adolescents</p></td><td style="vertical-align:top; width:117.0pt"><p>at least 50</p><p>30 to 49</p><p>10 to 29</p><p>less than 10</p></td><td style="vertical-align:top; width:131.25pt"><p><em>2 g twice in one day</em></p><p><em>1&nbsp;g twice in one day </em></p><p><em>500&nbsp;mg twice in one day </em></p><p><em>500&nbsp;mg once </em></p></td></tr><tr><td style="vertical-align:top; width:2.7in"><p>Herpes simplex prevention (suppression):</p></td><td style="vertical-align:top; width:117.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:131.25pt"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top; width:2.7in"><p>- immunocompetent adults and adolescents</p></td><td style="vertical-align:top; width:117.0pt"><p>at least 30</p><p>less than 30</p></td><td style="vertical-align:top; width:131.25pt"><p><em>500 mg once a day</em></p><p><em>250&nbsp;mg once a day</em></p></td></tr><tr><td style="vertical-align:top; width:2.7in"><p>- immunocompromised adults</p></td><td style="vertical-align:top; width:117.0pt"><p>at least 30</p><p>less than 30</p></td><td style="vertical-align:top; width:131.25pt"><p><em>500 mg twice a day</em></p><p><em>500&nbsp;mg once a day</em></p><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top; width:2.7in"><p>Cytomegalovirus (prophylaxis) in adults and adolescents</p></td><td style="vertical-align:top; width:117.0pt"><p>at least 75</p><p>50 to less than 75</p><p>25 to less than 50</p><p>10 to less than 25</p><p>less than 10 or on dialysis</p></td><td style="vertical-align:top; width:131.25pt"><p><em>2 g four times a day</em></p><p><em>1.5 g four times a day</em></p><p><em>1.5 g three times a day</em></p><p><em>1.5 g twice a day</em></p><p><em>1.5 g once a day</em></p></td></tr></tbody></table><p>In patients on intermittent haemodialysis, the <em>VALTREX</em> dosage recommended for patients with a creatinine clearance<strong> </strong>of less than 15&nbsp;mL/min should be used. This should be administered after the haemodialysis has been performed.</p><p>The creatinine clearance should be monitored frequently, especially during periods when renal function is changing rapidly, e.g. immediately after transplantation or engraftment. The <em>VALTREX</em> dosage should be adjusted accordingly.</p><ul><li><strong>Hepatic impairment</strong></li></ul><p>Studies with a 1 g unit dose of <em>VALTREX</em> show that dose modification is not required in patients with mild or moderate cirrhosis (hepatic synthetic function maintained). Pharmacokinetic data in patients with advanced cirrhosis, (impaired hepatic synthetic function and evidence of portal-systemic shunting) do not indicate the need for dosage adjustment; however, clinical experience is limited. For higher doses (4&nbsp;g or more/day),<s> </s>see <em>Warnings and Precautions</em>.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VALTREX is contra-indicated in patients known to be hypersensitive to valaciclovir, aciclovir or any components of formulations of VALTREX.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Hydration status:</em></strong> Care should be taken to ensure adequate fluid intake in patients who are at risk of dehydration, particularly the elderly.</p><p><strong><em>Use in patients with renal impairment and in elderly patients: </em></strong>Aciclovir is eliminated by renal clearance, therefore the dose of valaciclovir must be reduced in patients with renal impairment (<em>see Dosage and Administration</em>). Elderly patients are likely to have reduced renal function and therefore the need for dose reduction must be considered in this group of patients. Both elderly patients and patients with renal impairment are at increased risk of developing neurological side effects and should be closely monitored for evidence of these effects. In the reported cases, these reactions were generally reversible on discontinuation of treatment (<em>see Adverse Reactions</em>).</p><p><strong><em>Use of higher doses of VALTREX in hepatic impairment and liver transplantation: </em></strong>There are no data available on the use of higher doses of <em>VALTREX</em> (4&nbsp;g or more/day) in patients with liver disease. Caution should therefore be exercised when administering higher doses of <em>VALTREX</em> to these patients. Specific studies of <em>VALTREX</em> have not been conducted in liver transplantation; however high dose aciclovir prophylaxis has been shown to reduce CMV infection and disease.</p><p>Use in genital herpes: Suppressive therapy with VALTREX reduces the risk of transmitting genital herpes. It does not cure genital herpes or completely eliminate the risk of transmission. In addition to therapy with VALTREX, it is recommended that patients use safer sex practices.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No clinically significant interactions have been identified.</p><p>Aciclovir is eliminated primarily unchanged in the urine via active renal tubular secretion. Any drugs administered concurrently that compete with this mechanism may increase aciclovir plasma concentrations following <em>VALTREX</em> administration.</p><p>Following 1g valaciclovir, cimetidine and probenecid increase the AUC of aciclovir by this mechanism, and reduce aciclovir renal clearance. However, no dosage adjustment is necessary at this dose because of the wide therapeutic index of aciclovir.</p><p>In patients receiving higher doses of <em>VALTREX</em> (4&nbsp;g or more/day), caution is required during concurrent administration with drugs which compete with aciclovir for elimination, because of the potential for increased plasma levels of one or both drugs or their metabolites. Increases in plasma AUCs of aciclovir and of the inactive metabolite of mycophenolate mofetil, an immunosuppressant agent used in transplant patients, have been shown when oral aciclovir and mycophenolate mofetil are co-administered.</p><p>Care is also required (with monitoring for changes in renal function) if administering higher doses of <em>VALTREX</em> (4&nbsp;g or more/day) with drugs which affect other aspects of renal physiology (e.g. cyclosporin, tacrolimus).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fertility</p><p>In animal studies, VALTREX did not affect fertility. However, high parenteral doses of aciclovir caused testicular effects in rats and dogs (see Preclinical Safety Data).</p><p>No human fertility studies were performed with VALTREX, but no changes in sperm count, motility or morphology were reported in 20 patients after 6 months of daily treatment with 400 mg to 1 g aciclovir.</p><p>Pregnancy</p><p>There are limited data on the use of <em>VALTREX</em> in pregnancy. <em>VALTREX</em> should only be used in pregnancy if the potential benefits of treatment outweigh the potential risk.</p><p>Pregnancy registries have documented the pregnancy outcomes in women exposed to <em>VALTREX</em> or to any formulation of <em>ZOVIRAX</em>&trade; (aciclovir, the active metabolite of <em>VALTREX</em>); 111 and 1246 outcomes (29 and 756 exposed during the first trimester of pregnancy), respectively, were obtained from women prospectively registered. The findings of the aciclovir pregnancy registry have not shown an increase in the number of birth defects amongst aciclovir-exposed subjects compared with the general population, and any birth defects showed no uniqueness or consistent pattern to suggest a common cause. Given the small number of women enrolled into the valaciclovir pregnancy registry, reliable and definitive conclusions could not be reached regarding the safety of <em>VALTREX</em> in pregnancy (<em>see Pharmacokinetics</em>).</p><p>&nbsp;</p><p>Lactation</p><p>Aciclovir, the principle metabolite of <em>VALTREX</em>, is excreted in breast milk. Following oral administration of a 500 mg dose of <em>VALTREX</em>, peak aciclovir concentrations (C<sub>max</sub>) in breast milk ranged from 0.5 to 2.3 (median 1.4) times the corresponding maternal aciclovir serum concentrations. The aciclovir breast milk to maternal serum AUC ratios ranged from 1.4 to 2.6 (median 2.2). The median aciclovir concentration in breast milk was 2.24 micrograms/mL (9.95 micromoles). With a maternal <em>VALTREX</em> dosage of 500 mg twice daily, this level would expose a nursing infant to a daily oral aciclovir dosage of about 0.61 mg/kg/day. The elimination half-life of aciclovir from breast milk was similar to that for serum.</p><p>Unchanged valaciclovir was not detected in maternal serum, breast milk, or infant urine.</p><p>Caution is advised if <em>VALTREX</em> is to be administered to a nursing woman. However, <em>ZOVIRAX </em>is used to treat neonatal herpes simplex at intravenous doses of 30&nbsp;mg/kg/day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The clinical status of the patient and the adverse event profile of <em>VALTREX</em> should be borne in mind when considering the patient&rsquo;s ability to drive or operate machinery. There have been no studies to investigate the effect of valaciclovir<em> </em>on driving performance or the ability to operate machinery. Further, a detrimental effect on such activities cannot be predicted from the pharmacology of the active substance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions are listed below by MedDRA body system organ class and by frequency.</p><p>The frequency categories used are:<br />very common&nbsp; &sup3; 1 in 10,<br />common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &sup3; 1 in 100 and &lt; 1 in 10,<br />uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &sup3; 1 in 1,000 and &lt; 1 in 100,<br />rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &sup3; 1 in 10,000 and &lt; 1 in 1,000,<br />very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1 in 10,000.</p><p>Clinical trial data have been used to assign frequency categories to adverse reactions if, in the trials, there was evidence of an association with <em>VALTREX</em> (i.e. there was a statistically significant difference between the incidence in patients taking <em>VALTREX</em> and placebo). For all other adverse events, spontaneous post-marketing data have been used as a basis for allocating frequency.</p><p><strong>Clinical Trial Data</strong></p><p><strong>Nervous system disorders</strong></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>Gastrointestinal disorders</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea.</p><p><strong>Post Marketing Data</strong></p><p><strong>Blood and lymphatic system disorders</strong></p><p>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leukopenia, thrombocytopenia.</p><p>Leukopenia is mainly reported in immunocompromised patients.</p><p>Immune system disorders</p><p>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylaxis.</p><p>Psychiatric and nervous system disorders</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, confusion, hallucinations, decreased consciousness.</p><p>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Agitation, tremor, ataxia, dysarthria, psychotic symptoms, convulsions, encephalopathy, coma.</p><p>The above events are generally reversible and usually seen in patients with renal impairment or with other predisposing factors <em>(see Warnings and Precautions). </em>In organ transplant patients receiving high doses (8&nbsp;g daily) of <em>VALTREX</em> for CMV prophylaxis, neurological reactions occurred more frequently compared with lower doses.</p><p>Respiratory, thoracic and mediastinal disorders</p><p>Uncommon:&nbsp;&nbsp;&nbsp; Dyspnoea.</p><p>Gastrointestinal disorders</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal discomfort, vomiting, diarrhoea.</p><p>Hepatobiliary disorders</p><p>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reversible increases in liver function tests.</p><p>These are occasionally described as hepatitis.</p><p>Skin and subcutaneous tissue disorders</p><p>Uncommon:&nbsp;&nbsp;&nbsp; Rashes including photosensitivity.</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pruritus.</p><p>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urticaria, angioedema.</p><p>Renal and urinary disorders</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal impairment.</p><p>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute renal failure, renal pain.</p><p>Renal pain may be associated with renal failure.</p><p><strong>Other</strong><em>:</em> There have been reports of renal insufficiency, microangiopathic haemolytic anaemia and thrombocytopenia (sometimes in combination) in severely immunocompromised patients, particularly those with advanced HIV disease, receiving high doses (8&nbsp;g daily) of <em>VALTREX</em> for prolonged periods in clinical trials. These findings have been observed in patients not treated with <em>VALTREX</em> who have the same underlying or concurrent conditions.</p><p><strong>To report any side effect(s):</strong></p><p><strong>&nbsp;</strong></p><p><strong>Kingdom of Saudi Arabia</strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Fax: +966-11-205-7662</li><li>Call NPC at +966-11-2038222, Ext: 2317-2356-2340</li><li>Reporting Hotline: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: <u>www.sfda.gov.sa/npc </u></li></ul><p>&nbsp;</p><p><strong>-GlaxoSmithKline - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: <u>saudi.safety@gsk.com&nbsp; </u></li><li>Website: <u>https://gskpro.com/en-sa/ </u></li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms and signs</strong></p><p>Acute renal failure and neurological symptoms, including confusion, hallucinations, agitation, decreased consciousness and coma, have been reported in patients receiving overdoses of valaciclovir. Nausea and vomiting may also occur. Caution is required to prevent inadvertent overdosing. Many of the reported cases involved renally impaired and elderly patients receiving repeated overdoses, due to lack of appropriate dosage reduction.</p><p><strong>Treatment</strong></p><p>Patients should be observed closely for signs of toxicity. Haemodialysis significantly enhances the removal of aciclovir from the blood and may, therefore, be considered a management option in the event of symptomatic overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code</p><p>J05A B11</p><p>Mechanism of action</p><p>Valaciclovir, an antiviral, is the L-valine ester of aciclovir. Aciclovir is a purine (guanine) nucleoside analogue.</p><p>Valaciclovir is rapidly and almost completely converted in man to aciclovir and valine, probably by the enzyme referred to as valaciclovir hydrolase.</p><p>Aciclovir is a specific inhibitor of the herpes viruses with in vitro activity against herpes simplex viruses (HSV) type 1 and type 2, varicella zoster virus (VZV), cytomegalovirus (CMV), Epstein-Barr Virus (EBV), and human herpes virus 6 (HHV-6). Aciclovir inhibits herpes virus DNA synthesis once it has been phosphorylated to the active triphosphate form.</p><p>The first stage of phosphorylation requires the activity of a virus-specific enzyme. In the case of HSV, VZV and EBV this enzyme is the viral thymidine kinase (TK), which is only present in virus infected cells. Selectivity is maintained in CMV with phosphorylation, at least in part, being mediated through the phosphotransferase gene product of UL97. This requirement for activation of aciclovir by a virus specific enzyme largely explains its selectivity.</p><p>The phosphorylation process is completed (conversion from mono- to triphosphate) by cellular kinases. Aciclovir triphosphate competitively inhibits the virus DNA polymerase and incorporation of this nucleoside analogue result in obligate chain termination, halting virus DNA synthesis and thus blocking virus replication.</p><p>Pharmacodynamic effects</p><p>Resistance is normally due to a thymidine kinase deficient phenotype which results in a virus which is profoundly disadvantaged in the natural host. Infrequently, reduced sensitivity to aciclovir has been described as a result of subtle alterations in either the virus thymidine kinase or DNA polymerase. The virulence of these variants resembles that of the wild-type virus.</p><p>Extensive monitoring of clinical HSV and VZV isolates from patients receiving aciclovir therapy or prophylaxis has revealed that virus with reduced sensitivity to aciclovir is extremely rare in the immunocompetent and is only found infrequently in severely immunocompromised individuals e.g. organ or bone marrow transplant recipients, patients receiving chemotherapy for malignant disease and people infected with the human immunodeficiency virus (HIV).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>After oral administration valaciclovir is well absorbed and rapidly and almost completely converted to aciclovir and valine. This conversion is probably mediated by an enzyme isolated from human liver referred to as valaciclovir hydrolase.</p><p>The bioavailability of aciclovir from 1000&nbsp;mg valaciclovir is 54%, and is not reduced by food. VALTREX pharmacokinetics are not dose-proportional. The rate and extent of absorption decrease with increasing dose, resulting in a less than proportional increase in C<sub>max</sub> over the therapeutic dose range and a reduced bioavailability at doses above 500&nbsp;mg. Mean peak aciclovir concentrations are 10 to 37&nbsp;micromoles (2.2 to 8.3&nbsp;micrograms/mL) following single doses of 250 to 2000&nbsp;mg valaciclovir to healthy subjects with normal renal function, and occur at a median time of 1 to 2 h post dose.</p><p>Peak plasma concentrations of valaciclovir are only 4% of aciclovir levels, occur at a median time of 30 to 100 min post dose, and are at or below the limit of quantification 3&nbsp;h after dosing. The valaciclovir and aciclovir pharmacokinetic profiles are similar after single and repeat dosing.</p><p>Herpes zoster and herpes simplex do not significantly alter the pharmacokinetics of valaciclovir and aciclovir after oral administration of valaciclovir.</p><p>Distribution</p><p>Binding of valaciclovir to plasma proteins is very low (15%). CSF penetration, determined by CSF/plasma AUC ratio, is about 25% for aciclovir and the metabolite 8-hydroxy-aciclovir (8-OH-ACV), and about 2.5% for the metabolite 9-(carboxymethoxy)methylguanine (CMMG) (see Pharmacokinetics: Special Patient Populations).</p><p>Metabolism</p><p>After oral administration, VALTREX is converted to aciclovir and L-valine by first-pass intestinal and/or hepatic metabolism. Aciclovir is converted to a small extent to the metabolites 9-(carboxymethoxy)methylguanine (CMMG) by alcohol and aldehyde dehydrogenase and to 8-hydroxy-aciclovir (8-OH-ACV) by aldehyde oxidase. Approximately 88% of the total combined plasma exposure is attributable to aciclovir, 11% to CMMG and 1% to 8-OH-ACV. Neither VALTREX nor aciclovir is metabolised by cytochrome P450 enzymes.</p><p>Elimination</p><p>In patients with normal renal function the plasma elimination half-life of aciclovir after both single and multiple dosing with valaciclovir is approximately 3 h. Less than 1% of the administered dose of valaciclovir is recovered in the urine as unchanged drug. Valaciclovir is eliminated in the urine principally as aciclovir (greater than 80% of the recovered dose) and the known aciclovir metabolite, 9-(carboxymethoxy) methylguanine (CMMG).</p><p>Special Patient Populations</p><p><strong>Renal impairment</strong></p><p>The elimination of aciclovir is correlated to renal function, and exposure to aciclovir will increase with increased renal impairment. In patients with end-stage renal disease, the average elimination half-life of aciclovir after VALTREX administration is approximately 14 hours, compared with about 3 hours for normal renal function (see Dosing and Administration).</p><p>Exposure to aciclovir and its metabolites CMMG and 8-OH-ACV in plasma and cerebrospinal fluid (CSF) was evaluated at steady-state after multiple-dose VALTREX administration in 6 subjects with normal renal function (mean creatinine clearance 111 mL/min, range 91-144 mL/min) receiving 2000 mg every 6 hours and 3 subjects with severe renal impairment (mean CLcr 26 mL/min, range 17-31 mL/min) receiving 1500 mg every 12 hours. In plasma as well as CSF, concentrations of aciclovir, CMMG and 8-OH-ACV were on average 2, 4 and 5-6 times higher, respectively, in severe renal impairment compared with normal renal function. There was no difference in extent of CSF penetration (as determined by CSF/plasma AUC ratio) for aciclovir, CMMG or 8-OH-aciclovir between the two populations (see Pharmacokinetics: Distribution).</p><p><strong>Hepatic impairment</strong></p><p>Pharmacokinetic data indicate that hepatic impairment decreases the rate of conversion of VALTREX to aciclovir but not the extent of conversion. Aciclovir half-life is not affected.</p><p><strong>Pregnant women</strong></p><p>In a study of the pharmacokinetics of VALTREX and aciclovir during late pregnancy, the steady-state daily aciclovir AUC following VALTREX 1000&nbsp;mg daily was approximately 2&nbsp;times greater than that observed with oral aciclovir at 1200&nbsp;mg daily.</p><p>For information on transfer into breast milk see Lactation section.</p><p><strong>HIV infection</strong></p><p>In patients with HIV infection, the disposition and pharmacokinetic characteristics of aciclovir after oral administration of single or multiple doses of 1000&nbsp;mg or 2000&nbsp;mg VALTREX are unaltered compared with healthy subjects.</p><p><strong>Organ transplantation</strong></p><p>In transplant recipients receiving VALTREX 2000&nbsp;mg 4&nbsp;times daily, aciclovir peak concentrations are similar to or greater than those in healthy volunteers receiving the same dose. The estimated daily AUCs are appreciably greater.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The results of mutagenicity tests <em>in vitro</em> and <em>in vivo</em> indicate that <em>VALTREX</em> is unlikely to pose a genetic risk to humans.</p><p>Valaciclovir was not carcinogenic in bio-assays performed in mice and rats.</p><p>Valaciclovir did not affect fertility in male or female rats dosed by the oral route.</p><p>At high parenteral doses of aciclovir testicular atrophy and aspermatogenesis have been observed in rats and dogs.</p><p>Valaciclovir was not teratogenic in rats or rabbits. Valaciclovir is almost completely metabolised to aciclovir. Subcutaneous administration of aciclovir in internationally accepted tests did not produce teratogenic effects in rats or rabbits. In additional studies in rats, foetal abnormalities were observed at subcutaneous doses that produced plasma levels of 100&nbsp;micrograms/mL and maternal toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:139.5pt"><p><strong>Tablet core</strong></p></td><td style="vertical-align:top; width:285.75pt"><p><strong>Film coat</strong></p></td></tr><tr><td style="vertical-align:top; width:139.5pt"><p>Microcrystalline cellulose</p><p>Crospovidone</p><p>Povidone</p><p>Magnesium stearate</p><p>Colloidal silicon dioxide</p><p>Purified water</p><p>&nbsp;</p></td><td style="vertical-align:top; width:285.75pt"><p>Hydroxypropylmethylcellulose</p><p>Titanium dioxide</p><p>Polyethylene glycol</p><p>Polysorbate 80 (500 and 1000&nbsp;mg tablets only)</p><p>Purified water</p><p>Carnauba wax</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No data.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablets are packed into blister packs prepared from unplasticised polyvinyl chloride and aluminium foil.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special instructions for use.</p><p>Not all presentations are available in every country.</p><p><em>VALTREX</em> and <em>ZOVIRAX</em> are trademarks owned by or licensed to GSK group of companies</p><p>&copy; 2020 GSK group of companies, all rights reserved.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:
Glaxo Wellcome S.A.*, Aranda, Spain
Avenida de Extremadura, 3. 09400 Aranda de Duero, Burgos (Spain)
Packaged by
Glaxo Saudi Arabia Ltd.* Jeddah, Kingdom of Saudi Arabia
Marketing Authorisation Holder 
Glaxo Saudi Arabia Ltd.* Jeddah, KSA
*member of the GlaxoSmithKline group of companies

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number: GDS 22/IPI04
Date of issue: 18 June 2012
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>